| et 99 ans
- | Pays :
- France
- | Organes :
- Prostate
- | Spécialités :
- Thérapies Ciblées
Extrait
AFFIRM: A multinational phase 3, randomized, double-blind, placebo-controlled efficacy and safety study of oral MDV3100 in patients with progressive castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy.
Extrait Scientifique
en cours d'intégration;